N/A N=28 Study: Study to Compare Video Miller Device to Direct Laryngoscopy
Surgeries Undergoing General Anesthesia
Primary: Time to Obtain Glottic View — 9.2; 8.4 seconds
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=50 Study of AMG 531 to Evaluate the Safety & Efficacy in Patients With Non-Hodgkin's Lymphoma
Lymphoma
Primary: Platelet (PLT) Nadir — 20.3; 26.3; 24.8; 22.5 K/μL
N/A N=114 Photobiomodulation for Plantar Fasciitis
Plantar Fascitis
Primary: Foot and Ankle Ability Measure (FAAM) — 66.2; 72.4; 69.9; 69.3 percentage of total score
Phase 3 N=673 An Integrated Assessment of the Safety and Effectiveness of Bexagliflozin for the Management of Essential Hypertension
Essential Hypertension
Primary: Change of the 24 Hour Mean Systolic Blood Pressure From Baseline (Day 1) to Week 12 — -8.86; -6.15 mm Hg — p=0.0025
Phase 3 N=1,235 Study to Investigate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years and Over With Moderate to Severe Atopic Dermatitis With the Option of Rescue Treatment in Flaring Subjects
Dermatitis · Dermatitis, Atopic · Eczema
Primary: Percentage of Participants With Loss of Response: Double-blind (DB) Period — 77.5; 39.6; 16.5 percentage of participants
Phase 3 N=1,272 Pyronaridine Artesunate (3:1) Versus Coartem® in P Falciparum Malaria Patients
Malaria
Primary: PCR-Corrected Adequate Clinical and Parasitological Response (ACPR) Rate on Day 28 — 99.5; 99.2 percentage of subjects — p=0.578
Phase 3 N=28 Peripheral Dopamine in Postural Tachycardia Syndrome
Postural Tachycardia Syndrome · Orthostatic Intolerance
Primary: 24 Hour Urinary Sodium Excretion During Treatment Normalized to Creatinine — 140; 132; 137; 154 Milliequivalents per gram (mEq/g)
Phase 3 N=83 Bupropion-Enhanced Contingency Management (CM) for Cocaine Dependence
Substance Abuse · Cocaine Dependence
Primary: Number of Cocaine Negative Urines — 70.6; 57.7; 4.2; 14.5 Mean percent negative urines — p=0.889
N/A N=211 REAL HEALTH-Diabetes: Reach Ahead for Lifestyle and Health-Diabetes
Type 2 Diabetes Mellitus · Obesity
Primary: Percent Weight Change From Baseline — -1.1; -5.6; -4.6; -2.0 percentage of weight
Phase 2 N=69 Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC)
Kidney Cancer
Primary: Progression Free Survival (PFS) — 2.7; 5.2 months
N/A N=15 Investigating Mechanisms Underlying Spinal Cord Stimulation Efficacy Using Virtual Reality and Full Body Illusion
Neuropathy;Peripheral
Primary: Average Pain Reduction Post Intervention — 2.72 score on a scale
Phase 2 N=495 A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer
Advanced Gastrointestinal Cancer
Primary: Number of Participants With Adverse Events and Serious Adverse Events — 115; 41; 87; 156 Participants
Phase 2 N=101 A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors
Metastatic Pancreatic Cancer · Colorectal Cancer · Esophageal Neoplasms
Primary: Percentage of Participants With Dose Limiting Toxicities (DLTs) in Western Safety Cohort — 50 percentage of participants
N/A N=30 Anesthesia With Endotracheal Laser Tube
Anesthesia · Anesthesia Morbidity
Primary: Number of Participants With Side Effects — 0 participants
Phase 2 N=46 Autologous CD34+ Hematopoietic Stem Cells Transduced ex Vivo With Elongation Factor 1 Alpha Shortened (EFS) Lentiviral Vector Encoding for the Human ADA Gene
ADA-SCID
Primary: Overall Survival (OS) of Subjects Treated With Investigational Medicinal Product (IMP) (1 Year) — 100; 85.71; 100; 92.31 percentage of participants